Form 8-K - Current report:
SEC Accession No. 0001493152-22-033864
Filing Date
2022-11-29
Accepted
2022-11-28 19:08:03
Documents
13
Period of Report
2022-11-23
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 57885
  Complete submission text file 0001493152-22-033864.txt   275267

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ptix-20221123.xsd EX-101.SCH 3721
3 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ptix-20221123_def.xml EX-101.DEF 26547
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ptix-20221123_lab.xml EX-101.LAB 36501
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ptix-20221123_pre.xml EX-101.PRE 25171
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5220
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 221427767
SIC: 7389 Services-Business Services, NEC